Drugs / Autologous Tumor Infiltrating Lymphocytes (TIL)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07183852 | Mar 2026 → Mar 2028 expected | cutaneous melanoma, uveal melanoma | Vastra Gotaland Region | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Tumor Infiltrating Lymphocytes (TIL) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07183852 ↗ |
| Route | Other | “Administered via hepatic arterial infusion” NCT07183852 ↗ |